After two years of negotiations, FDA gets its user fee programs authorized through 2022
President Donald Trump signed the FDA Reauthorization Act of 2017 into law late Friday, quietly ending a two-year long process that until several weeks ago threatened to disrupt agency operations.
Although the legislation was passed by both houses of Congress with overwhelming bipartisan support — Senator Bernie Sanders was the only registered no vote — it faced a number of threats, including the White House’s clear desire to fund the FDA entirely with user fees from the companies the agency regulates and a senator’s long standing crusade to undercut the agency with a sweeping new “right-to-try” directive.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.